BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Establishment of Distinct Business Unit, Aptuit Consulting, Inc. Coincides with Acquisition of Pharma Consulting Inc.


12/12/2007 7:53:16 AM

GREENWICH, CT, May 23, 2006 – Aptuit, Inc. announced today that it has formally launched Aptuit Consulting Inc., establishing a distinct business unit coinciding with the acquisition of Harvard, MA-based Pharma Consulting Inc. The new company will offer counsel and services from experienced industry professionals with proven track records in all aspects of drug development, helping clients move efficiently and successfully from IND-enabling chemistry and biology to proof-of-concept clinical studies.

The Aptuit Consulting business line will have offices in major life science centers around the globe and will serve both large and small biotech and pharmaceutical companies. Former Pharma Consulting Inc. CEO, William D. Kerns, D.V.M., will join Robert G. Burford, Ph.D., F.A.C.A., and Leslie Patmore, Ph.D., as Managing Directors of Aptuit Consulting. Under the terms of the agreement, Pharma Consulting Inc. will merge with Aptuit’s existing team to form a group with more extensive expertise and geographic coverage.

“Many of our customers at Aptuit are smaller biotechnology companies with promising molecules, but may lack the internal resources and expertise to effectively execute development of their product candidates,” noted Michael A. Griffith, CEO of Aptuit. “Our consultants are industry veterans who have guided successful drug candidates down the development path many times. They bring insight, experience, and project management skills that can make a major difference in how efficiently drug candidates move from one development milestone to the next.”

Dr. Kerns followed by saying, “It was Aptuit’s management team and novel approach to consulting that solidified my strategic decision to merge with the company. Aptuit has a tremendous breadth and depth of development expertise - yet they remain focused intently on minimizing the particular inefficiencies and complexities that hamper a drug candidate as it moves from milestone to milestone. Through my tenure as a pharmaceutical industry executive and consultant and working with several top-tier pharmaceutical companies and small biotechs, I have seen the pitfalls of the current process and look forward to bringing about innovation in the sector through this new merger. Our team will manage projects by accessing best-in-class resources to meet the service and strategic needs of our customers.”

In addition to Aptuit Consulting and Aptuit Informatics, Aptuit has a series of core operating business units, which include Active Pharmaceutical Ingredient Development (API), Preclinical Technologies, Analytics, Pharmaceutics, and Clinical Packaging and Logistics. Aptuit Informatics will spearhead development of the Company’s innovative end-to-end IT platform, allowing customers and the Aptuit organization the ability to track projects anywhere in the world, in real time. In addition, customers can opt to retain Aptuit consultants to manage projects in-house or at other drug development service providers.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES